Gilenya Works to Treat RRMS by Specifically Targeting B-cells and T-helper Cells, Study Finds
Treating people with relapsing-remitting multiple sclerosis (RRMS) for one year with the immune-modulating therapy Gilenya (fingolimod) reduced the numbers of antibody-producing B-cells and of T helper cells, a study finds. While the…